Drug manufacturer Merck sued the federal government on Friday over the government’s May 6 letter telling the company its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal. The government warned Merck it could be
…
Pharmaceutical Research and Manufacturers of America and drug maker Johnson & Johnson each filed a friend of the court brief in June backing Novartis and United Therapeutics in those two companies’ appeals of a federal district judge’s November decision that
…
Five groups that represent 340B hospitals have filed briefs in two federal appeals courts backing the federal government in its fight to force drug manufacturers Eli Lilly and AstraZeneca to end restrictions on 340B drug discounts when covered entities use
…
Drug manufacturers Novo Nordisk and Sanofi last month urged a federal appeals court to reverse a district judge’s ruling that the companies’ conditions on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.
Meanwhile, the federal government
…
A federal appeals court ruled unanimously this morning that a South Carolina health center has the right to challenge the legality of the government’s 340B patient definition in a lower federal court. The case ultimately could have profound implications for
…
The American Hospital Association wants to discuss with U.S. Health and Human Services Secretary Xavier Becerra how 340B hospitals should be promptly repaid “for all of the years (2018-2022) in which the Centers for Medicare & Medicaid Services (CMS) illegally
…
A federal district judge was right to decide that drug manufacturer Lilly cannot tie strings to 340B pricing on its drugs, the U.S. Justice Department told a federal appeals court in Chicago on Friday. But, DOJ said, the judge was
…
One of two groups of Florida health care providers that drug maker Gilead accused of making fraudulent 340B-related transactions involving the company’s HIV pre-exposure prophylaxis drugs agreed last week to settle Gilead’s claims against it for $33 million.
A mediation
…
A U.S. Supreme Court decision last week about the Medicare disproportionate share adjustment percentage calculation will have little effect on hospitals currently in the 340B drug pricing program, experts say. It could mean, though, that some on the cusp of
…
The U.S. Supreme Court’s unanimous June 15 ruling that huge cuts in 340B hospitals’ Medicare Part B drug reimbursement were unlawful “is a clear and much welcome victory for 340B hospitals,” 340B Report Publisher and CEO Ted Slafsky says in
…*Sign up for news summaries and alerts from 340B Report